Impetis Biosciences Limited

Kasim Mookhtiar

Bheemashankar A Kulkarni

Sujay Basu

Meena Patel

Dinesh Barawkar

Anil Panmand

Rajesh Bonagiri

Sachin Thorat

Yogesh Shejul

Goraksha Khose

Yogesh Munot

Debnath Bhuniya

Summon Koul

Keshav Naik

Santosh Kurhade

Manoj Joshi

Tanaji Mengawade

Amit Bhalerao

Mayur Mukim

Nadim Shaikh

Mahesh Thakkar

Shailesh Shinde

Partha Mukhopadhyay

The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.D-A-B—Z  (I)Formula I

Tricyclic compounds, compositions and medicinal applications thereof

The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III). 

Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.

Fused bicyclic compounds, compositions and applications thereof

Growing community of inventors

Mumbia, India

Kasim Mookhtiar